Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.48 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106519 | 0.85 | CA1 (0.53) | CA2CA1CA9CA12CA6 | |
| SCHEMBL30593603 | 0.85 | CA1 (0.53) | CA2CA1CA9CA12CA6 | |
| SCHEMBL6680955 | 0.85 | GAA (0.46) | CA2CA1CA9CA12ACHE | |
| SCHEMBL5140208 | 0.83 | L3MBTL1 (0.40) | CA2CA1CA9CA12ACHE | |
| SCHEMBL9493369 | 0.83 | CA1 (0.51) | CA2CA1CA9CA12CA6 | |
| Potassium SCHEMBL9493381 | 0.83 | CA1 (0.51) | CA2CA1CA9CA12CA6 | |
| Hydrochloric Acid SCHEMBL28262186 | 0.83 | CA1 (0.51) | CA2CA1CA9CA12CA6 | |
| SCHEMBL3284628 | 0.82 | HTR2A (0.48) | CA2CA1CA9CA12CA6 | |
| SCHEMBL14008998 | 0.82 | CYP1A2 (0.38) | CA2CA1CA9CA12ACHE | |
| SCHEMBL2517262 | 0.82 | MYC (0.42) | CYP1A2CYP3A4CYP2D6NFKB1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114235990-B | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2024-11-26 | — | — | CN | claimed |
| CN-114235990-A | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2022-03-25 | — | — | CN | claimed |
| EP-0783366-B1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | UNIV MASSEY (NZ) | 2004-08-18 | — | — | EP | claimed |
| US-5652348-A | SOLID SUPPORT MATRIX, IONIZABLE LIGANDS SELECTED RELATIVE TO TARGET COMPOUND | MASSEY UNIVERSITY (NZ) | 1997-07-29 | — | — | US | claimed |
| EP-0783366-A1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | MASSEY UNIVERSITY (NZ) | 1997-07-16 | — | — | EP | claimed |
| WO-1996009116-A1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | MASSEY UNIVERSITY (NZ) | 1996-03-28 | — | — | WO | claimed |
| CN-114235990-B | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-117732437-A | Preparation and drug target identification application of switchable sulfhydryl functional magnetic silica nanoparticle | 北京青莲百奥生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117732437-A | Preparation and drug target identification application of switchable sulfhydryl functional magnetic silica nanoparticle | 北京青莲百奥生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114235990-A | Tuberculosis serum marker screening method and application | 宁夏医科大学 | 2022-03-25 | — | — | CN | disclosed |
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2009140743-A2 | BLOOD IMAGING | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-11-26 | — | — | WO | disclosed |
| US-20080138291-A1 | Sulfonamide Derivatives Having Carbonic Anhydrase Inhibiting Activity and their Use as Therapeutic and Diagnostic Agents | UNION LIFE SCIENCES LTD. (GB) | 2008-06-12 | — | — | US | disclosed |
| WO-2006137092-A1 | FLUORESCENT SULFONAMIDE DERIVATIVES HAVING CARBONIC ANHYDRASE INHIBITING ACTIVITY AND THEIR USE AS THEAPEUTIC AND DIAGNOSTIC AGENTS | SUPURAN CLAUDIU T (IT) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137009-A2 | FLUORESCENT SULFONAMIDE DERIVATIVES HAVING CARBONIC ANHYDRASE INHIBITING ACTIVITY AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC AGENTS | UNION LIFE SCIENCES LTD (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-0783366-B1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | UNIV MASSEY (NZ) | 2004-08-18 | — | — | EP | disclosed |
| US-5945520-A | RESIN OF SOLID SUPPORT MATRIX, SPACER ARM AND IONIZABLE FUNCTIONALITY; SPECIFICALLY DESIGNED TO BIND THE TARGET COMPOUND FROM AN AQUEOUS SOLUTION AT BOTH A LOW AND HIGH IONIC STRENGTH | MASSEY UNIVERSITY (NZ) | 1999-08-31 | — | — | US | disclosed |
| US-5652348-A | SOLID SUPPORT MATRIX, IONIZABLE LIGANDS SELECTED RELATIVE TO TARGET COMPOUND | MASSEY UNIVERSITY (NZ) | 1997-07-29 | — | — | US | disclosed |
| EP-0783366-A1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | MASSEY UNIVERSITY (NZ) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996009116-A1 | CHROMATOGRAPHIC RESINS AND METHODS FOR USING SAME | MASSEY UNIVERSITY (NZ) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138291-A1 | Sulfonamide Derivatives Having Carbonic Anhydrase Inhibiting Activity and their Use as Therapeutic and Diagnostic Agents | CA9, CA4, CA2 | CA2 3/4885CA1 8/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.